Back to FARALLON CAPITAL MANAGEMENT, L.L.C.

PTGX
Showing 8 of 30 quarters

Position history for FARALLON CAPITAL MANAGEMENT, L.L.C.'s holdings in PROTAGONIST THERAPEUTICS INC

FARALLON CAPITAL MANAGEMENT, L.L.C. holds 6.3M shares of PTGX (PROTAGONIST THERAPEUTICS INC), worth $669.2M as of 2026-Q1. The position was increased (+3.3% shares). PTGX represents 3.8% of FARALLON CAPITAL MANAGEMENT, L.L.C.'s portfolio.

Current Value

$669.2M

Current Shares

6.3M

Total Value Change

+$466.8M

Total Shares Change

+508,133

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
6.3M
+3.3%
$669.2M3.8%$91.30
60
2025-Q4
Decreased
6.1M
-0.8%
$536.6M2.5%$87.26
0
2025-Q3
Increased
6.2M
+0.4%
$411.6M1.7%$65.14
49
2025-Q2
Increased
6.2M
+1.1%
$341.1M1.5%$55.69
49
2025-Q1
Increased
6.1M
+3.0%
$295.3M1.6%$48.88
50
2024-Q4
Increased
5.9M
+1.2%
$228.9M1.2%$38.51
49
2024-Q3
Increased
5.9M
+0.3%
$263.7M1.3%$44.56
49
2024-Q2
Increased
5.8M
+1.8%
$202.4M1.0%$34.65
44

Other major holders of PTGX: BlackRock, Inc., UBS Group AG, RTW INVESTMENTS, LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used